Phosphoinositide (PI) pathways regulate fundamental processes of cellular growth and metabolism. The importance of PI signaling in human health is underscored by the many diseases that arise from PI pathway deregulation. PI-modifying enzymes are among the most frequently mutated proteins in cancer.
Nonetheless, very few drugs have been developed that successfully disrupt oncogenic signaling in PI pathways. Petra believes that a refined understanding of the highly complex biology of these pathways is necessary to target the right steps or branches in the pathways to yield effective and safe therapies.
The founders and partners of Petra bring together comprehensive understanding of the biology of PI signaling with the most advanced drug discovery technologies in the world.